Arkan Zwick Q&A, Part 2: EU Combo-Product Review Challenges
In the second half of a Q&A with Medtech Insight, Croma Pharma executive Arkan Zwick talks about the challenges of getting the drug element of a device-type combination product reviewed in the EU and what combo-product firms have to look out for under the oncoming Medical Devices Regulation. Read the first part of the conversation here.
You may also be interested in...
Arkan Zwick Q&A, Part 1: Choosing An EU Notified Body For Drug/Device Combinations In A Rapidly Changing Environment
Selecting a notified body that has capacity, expertise and staying power is a challenge in itself. But when it comes to selecting a good one for drug/device combinations products, how should companies proceed? Croma Pharma executive Arkan Zwick offers his insight in this first part of a two-part Q&A. Check out the second part here.
There are very few regulatory hurdles to placing a COVID-19 test on the EU market under the IVD Directive. This situation, however, is changing under the IVD Regulation. The European Commission explains what manufacturers need to weigh up when deciding their regulatory pathway.
When Will A Notified Body Conduct An MDR/IVDR Virtual Audit And How? BSI Netherlands Gives Its Views
When it comes to notified bodies deciding whether to undertake virtual audits or not in the context of the new EU medtech regulations, there are many elements that need considering and many different potential responses and cost implications. In this interview, BSI Netherlands explains its approach.